Pulmonx Q2 revenue $22.8M (-5% YoY); net loss narrows to $10.1M

Pulmonx Corp

Revenue $22.8M, down 5% YoY; U.S. $14.2M (-4%), international $8.6M (-6%; ex-China +12%).
Record gross margin 78% (vs 72% YoY); operating expenses down 16% to $26.8M.
Net loss $10.1M ($0.24/share) vs $15.2M loss; adjusted EBITDA loss $5.1M, down 39%.
Cash $55.8M; FY2026 guidance: revenue $90-92M, gross margin ~76%, opex $109-111M.
Management cites cost realignment and expects return to year-over-year revenue growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.